WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007002972) USE OF A COMPOUND FOR ENHANCING THE EXPRESSION OF MEMBRANE PROTEINS ON THE CELL SURFACE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/002972    International Application No.:    PCT/AT2006/000282
Publication Date: 11.01.2007 International Filing Date: 03.07.2006
IPC:
A61K 38/05 (2006.01), A61K 38/16 (2006.01), A61P 3/06 (2006.01), A61P 9/06 (2006.01), A61P 11/00 (2006.01), A61P 43/00 (2006.01)
Applicants: BIODEVELOPS PHARMA ENTWICKLUNG GMBH [AT/AT]; Währinger Strasse 13A, A-1090 Wien (AT) (For All Designated States Except US).
FREISSMUTH, Michael [AT/AT]; (AT) (For US Only).
KIRPENKO, Tetyana [UA/AT]; (AT) (For US Only).
NANOFF, Christian [AT/AT]; (AT) (For US Only).
KORKHOV, Volodymyr, M. [UA/AT]; (AT) (For US Only)
Inventors: FREISSMUTH, Michael; (AT).
KIRPENKO, Tetyana; (AT).
NANOFF, Christian; (AT).
KORKHOV, Volodymyr, M.; (AT)
Agent: NEMEC, Harald; Wipplingerstrasse 32/22, A-1010 Wien (AT)
Priority Data:
1144/2005 06.07.2005 AT
Title (EN) USE OF A COMPOUND FOR ENHANCING THE EXPRESSION OF MEMBRANE PROTEINS ON THE CELL SURFACE
(FR) UTILISATION D'UN COMPOSE PERMETTANT D'AMELIORER L'EXPRESSION DES PROTEINES MEMBRANAIRES SUR LA SURFACE D'UNE CELLULE
Abstract: front page image
(EN)The present invention is directed to the use of Bortezomib and/or a pharmaceutically acceptable salt or ester thereof for the manufacture of a medicament for enhancing the expression of membrane proteins on the cell surface. Especially, the invention is directed to the use of Bortezomib for the manufacture of a medicament for the treatment of a disease of condition selected from the group consisting of cystic fibrosis, diabetes insipidus, hypercholesterinaemia and long QT-syndrome-2.
(FR)L'invention concerne l'utilisation du bortézomib et/ou d'un sel ou d'un ester de celui-ci pharmaceutiquement acceptable pour produire un médicament permettant d'améliorer l'expression des protéines membranaires sur la surface d'une cellule. L'invention concerne, en particulier, l'utilisation du bortézomib pour produire un médicament permettant de traiter une maladie ou une affection sélectionnée dans le groupe constitué par la fibrose kystique, le diabète insipide, l'hypercholestérolémie et le syndrome du QT long de type 2.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)